QPPV.COM KNOWLEDGE ASSESSMENT

Risk Management Plans: EU Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Risk Management Plans (RMPs).

Question 1 of 10Pass mark: 80%

Question 1 of 10 A significant new safety issue has been identified and may require a change to the RMP. What is the most appropriate governance response?

Defer assessment until routine annual document maintenance Initiate documented escalation, assess significance, determine required changes and notify authorities without undue delay where applicable Update only the internal safety database and wait for a request from inspectors Change the RMP text without recording the evidence or approval pathway

Question 2 of 10 Which statement best describes the lifecycle nature of an RMP?

It is finalised at initial authorisation and remains unchanged unless the product is withdrawn It is updated only when a regulator explicitly requests a revision It evolves as new evidence emerges from signals, studies, literature, regulatory reviews and routine pharmacovigilance It is replaced by the PSUR or PBRER once sufficient post-authorisation data are available

Question 3 of 10 Which document set would provide the strongest inspection evidence that an RMP change was properly controlled?

Only the current RMP and a draft email announcing the change A signal or study assessment, governance minutes, decision rationale, tracked RMP revision, approvals, submission evidence and implementation records Only the final educational material used after implementation A list of adverse events without causality assessments or decision records

Question 4 of 10 What should each additional pharmacovigilance activity in an RMP include?

Only the study title and the name of the responsible department A link to the concern addressed, objective, timelines, milestones, deliverables and responsibilities A commitment to collect all adverse events regardless of relevance A risk minimisation measure but no defined data-generation objective

Question 5 of 10 Which metric is a proximal outcome for a measure intended to improve laboratory monitoring?

Number of educational letters printed Percentage of prescribers who attended a webinar Percentage of treated patients receiving baseline and periodic monitoring Number of RMP Working Group meetings held

Question 6 of 10 Which statement best describes the QPPV's role in relation to RMPs?

The QPPV must personally draft every section of every RMP The QPPV may delegate all RMP oversight because specialised functions author the document The QPPV should maintain awareness of key concerns and activities, oversee governance and demonstrate that significant decisions and submissions are timely, evidence-based and auditable The QPPV's role is limited to signing the cover page without reviewing the content

Question 7 of 10 Which is generally a routine risk minimisation measure?

A controlled access programme A pregnancy prevention programme Product information and prescribing information A mandatory prescriber certification programme

Question 8 of 10 Why may important safety concerns remain incompletely understood when a medicinal product receives marketing authorisation?

Pre-authorisation studies generally include unlimited patient numbers and long-term real-world follow-up Clinical development is conducted under controlled conditions with restricted populations and study durations Regulators do not assess safety information before authorisation Post-authorisation pharmacovigilance is not permitted to generate new safety information

Question 9 of 10 Why is measuring distribution of an educational guide alone insufficient to demonstrate effectiveness?

Distribution metrics are prohibited for additional risk minimisation measures Distribution confirms implementation but does not establish knowledge, behaviour change or improved health outcomes Effectiveness can only be assessed through spontaneous reports Educational measures do not require any evaluation

Question 10 of 10 When is an additional risk minimisation measure most appropriately considered?

Whenever any non-serious adverse event is reported When routine measures alone are insufficient to control an important risk Only after a product has been withdrawn Whenever the company wants to increase product awareness

Risk Management Plans: EU Pharmacovigilance Knowledge Assessment

Cookie Settings